LIVE WEBINAR: Thursday, July 6, 2023, 5:00 PM – 6:00 PM Eastern Time

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Chronic Lymphocytic Leukemia

Part 3 of a 3-Part Complimentary NCPD Webinar Series in Partnership with the 2023 ONS Congress

 

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, July 6th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Kristen E Battiato, AGNP-C
Advanced Practice Providers
Memorial Sloan Kettering Cancer Center
New York, New York

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Thursday, July 6, 2023
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • The Relevance of Biomarker Testing in Chronic Lymphocytic Leukemia (CLL)
  • First-Line Therapy for Newly Diagnosed CLL
  • The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL
  • Toxicities and Other Practical Considerations with BTK Inhibitors
  • The Tolerability and Duration of Venetoclax-Based Treatment
  • The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax
  • Available Therapies for R/R CLL and Promising Investigational Agents and Strategies

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options. 
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and explain to patients the risks and potential benefits of time-limited therapy. 
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL. 
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL. 
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL, and provide corresponding education to patients.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
https://www.researchtopractice.com/Meetings/postONS2023/CLL/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Battiato has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr WoyachAdvisory Committee and Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.